Airain Ltd’s Standard BioTools LAB Stock Holding History

Airain Ltd’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-15,524	Closed	-$168K	–	945
2015 Q4	$168K	Buy	+15,524	New	+$152K	0.01%	741

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RFC

Russell Frank Company Seattle, Washington $56.9B AUM 2.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Airain Ltd's LAB Position: Q1 2016 in Review

Airain Ltd sold out of Standard BioTools (LAB) in Q1 2016, closing a stake of 15,524 shares — an estimated $168K sold.

Airain Ltd first reported a position in LAB in Q4 2015 and held it in 1 quarter. The position peaked at $168K in Q4 2015. 100 funds tracked by Wall St. Rank hold LAB as of Q1 2016.

Airain Ltd reported no remaining Standard BioTools position as of Q1 2016 after selling out during the quarter.
Airain Ltd sold 15,524 Standard BioTools shares in Q1 2016, an estimated $168K.
Airain Ltd first reported a position in Standard BioTools in Q4 2015 and held it in 1 quarter.
Airain Ltd's Standard BioTools position peaked at $168K in Q4 2015.
100 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2016.

Based on Airain Ltd's 13F filing for Q1 2016, filed 9 May 2016.